HC Wainwright Predicts Liquidia’s Q1 Earnings (NASDAQ:LQDA)

Liquidia Co. (NASDAQ:LQDA) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for Liquidia in a report released on Thursday, March 20th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.49) per share for the quarter. HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.07) EPS.

Several other brokerages have also recently commented on LQDA. Scotiabank raised their target price on Liquidia from $30.00 to $34.00 and gave the stock a “sector outperform” rating in a research report on Thursday, March 20th. Needham & Company LLC raised their price objective on shares of Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. Finally, Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Liquidia presently has an average rating of “Buy” and an average target price of $26.63.

Liquidia Trading Down 0.4 %

Shares of LQDA stock opened at $15.60 on Monday. The company has a market capitalization of $1.33 billion, a P/E ratio of -9.57 and a beta of 0.07. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.81. The stock has a 50 day moving average of $14.95 and a two-hundred day moving average of $12.32.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million.

Institutional Investors Weigh In On Liquidia

Hedge funds and other institutional investors have recently made changes to their positions in the stock. LM Advisors LLC acquired a new stake in shares of Liquidia in the fourth quarter valued at approximately $25,948,000. Whitefort Capital Management LP boosted its position in Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after purchasing an additional 927,546 shares during the last quarter. Invesco Ltd. grew its stake in Liquidia by 2,675.0% in the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company’s stock valued at $8,234,000 after purchasing an additional 674,940 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Liquidia by 1,484.5% during the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company’s stock worth $6,293,000 after purchasing an additional 501,752 shares during the last quarter. Finally, Mirabella Financial Services LLP bought a new stake in shares of Liquidia during the 4th quarter worth approximately $5,880,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Rajeev Saggar sold 2,445 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the transaction, the insider now owns 267,943 shares of the company’s stock, valued at $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Russell Schundler sold 16,393 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the sale, the general counsel now owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. The trade was a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,245 shares of company stock worth $843,326. Insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).